XNCR is up 15.89% today. Volume is 8.89M vs a 30-day average of 1.46M (6.11x).
Xencor, Inc. is scheduled to report earnings Mon, Nov 9, 2026. Analysts expect EPS of $-0.59 on revenue of about $57.54M. Stocks often move sharply on earnings day.
Xencor reported updated Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma, selecting a 400 mcg/kg intravenous dose as the proposed Phase 3 regimen after enrolli…
Xencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carc…
Xencor (NASDAQ:XNCR) shares jumped 20% to $30.18 on Monday after updated clinical trial results for its experimental kidney cancer drug XmAb819 supported plans for later-stage dev…
SGRY led gap-ups at 46.25% and XP led gap-downs at -50.48% in today's session, with SPRC, RENT, XNCR, XXII, DAICW and AGBK among notable gap movers.
Investing.com -- Xencor Inc (NASDAQ:XNCR) shares jumped 24% Monday following the presentation of Phase 1 dose selection data for XmAb819, a bispecific T-cell engager in developmen…